pharma · Polycythemia Vera · Ulcerative Colitis Chronic Moderate · PTGX
Protagonist Therapeutics
Protagonist Therapeutics, Inc
Protagonist Therapeutics clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 7707 Gateway Blvd, Suite 140, Newark, California 94560, US
- Founded
- 2006
- Employees
- 153
- Programs
- 13
- Drugs
- 5
- Patents
- 33
Protagonist Therapeutics projects
13 ClinicalTrials.gov programs sponsored by Protagonist Therapeutics.
Protagonist Therapeutics has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Open-label rusfertide
Protagonist Therapeutics, Inc
Polycythemia Vera
1 trial -
Placebo
Protagonist Therapeutics, Inc
Polycythemia Vera
1 trial -
VERIFY
Protagonist Therapeutics, Inc
Polycythemia Vera
1 trial -
PN-943
Protagonist Therapeutics, Inc
Ulcerative Colitis Chronic Moderate
1 trial -
PTG-100
Protagonist Therapeutics, Inc
Ulcerative Colitis
1 trial -
PTG-300
Protagonist Therapeutics, Inc
Hereditary Hemochromatosis
1 trial -
PTG-300
Protagonist Therapeutics, Inc
β-thalassemia
2 trials -
PTG-300
Protagonist Therapeutics, Inc
Polycythemia Vera
2 trials -
PN-232
Protagonist Therapeutics, Inc
Healthy Subjects
1 trial -
PN-235
Protagonist Therapeutics, Inc
Healthy Volunteers
1 trial -
PN-881 Oral Solution
Protagonist Therapeutics, Inc
Healthy Volunteer
1 trial -
PTG-100
Protagonist Therapeutics, Inc
Celiac Disease
1 trial -
PTG-300
Protagonist Therapeutics, Inc
Healthy Volunteers
1 trial
Frequently asked questions
How many clinical projects does Protagonist Therapeutics have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.